[1] Malik MU, Pandian V, Masood H, et al. Spectrum of immune-mediated inner ear disease and cochlear implant results[J]. Laryngoscope, 2012,122(11):2557-2562. DOI: 10.1002/lary.23604.
[2] Psillas G, Dimas GG, Savopoulos C, et al. Autoimmune hearing loss: a diagnostic challenge[J]. J Clin Med, 2022,11(15):4601. DOI: 10.3390/jcm11154601.
[3] Lee JM, Kim JY, Bok J, et al. Identification of evidence for autoimmune pathology of bilateral sudden sensorineural hearing loss using proteomic analysis[J]. Clin Immunol, 2017,183:24-35. DOI: 10.1016/j.clim.2017.06.008.
[4] Goodall AF, Siddiq MA. Current understanding of the pathogenesis of autoimmune inner ear disease: a review[J]. Clin Otolaryngol, 2015,40(5):412-419. DOI: 10.1111/coa.12432.
[5] 王涛,刘少峰,王文,等.自身免疫性内耳病的诊治进展[J].国际耳鼻咽喉头颈外科杂志,2017,41(6):337-340.DOI:10.3760/cma.j.issn.1673-4106.2017.06.006.
[6] García Berrocal JR, Ramírez-Camacho R, et al. Does the serological testing really play a role in the diagnosis immune-mediated inner ear disease?[J]. Acta Otolaryngol, 2002,122(3):243-248. DOI: 10.1080/000164802753648105.
[7] McCabe BF. Autoimmune sensorineural hearing loss[J]. Ann Otol Rhinol Laryngol, 1979,88(5 Pt 1):585-859. DOI: 10.1177/000348947908800501.
[8] Billings PB, Keithley EM, Harris JP. Evidence linking the 68 kilodalton antigen identified in progressive sensorineural hearing loss patient sera with heat shock protein 70[J]. Ann Otol Rhinol Laryngol, 1995,104(3):181-188. DOI: 10.1177/000348949510400302.
[9] Lorenz RR, Solares CA, Williams P, et al. Interferon-gamma production to inner ear antigens by T cells from patients with autoimmune sensorineural hearing loss[J]. J Neuroimmunol, 2002,130(1-2):173-178. DOI: 10.1016/s0165-5728(02)00190-x.
[10] Li G, You D, Ma J, et al. The role of autoimmunity in the pathogenesis of sudden sensorineural hearing loss[J]. Neural Plast, 2018,2018:7691473. DOI: 10.1155/2018/7691473.
[11] Wik JA, Skålhegg BS. T Cell metabolism in infection[J]. Front Immunol, 2022,13:840610. DOI: 10.3389/fimmu.2022.840610.
[12] Gloddek B, Arnold W. Clinical and experimental studies of autoimmune inner ear disease[J]. Acta Otolaryngol Suppl, 2002(548):10-14. DOI: 10.1080/00016480260094901.
[13] 滕济森,李圣杰,李晓娟,等.突发性耳聋与血脂、免疫球蛋白水平以及凝血功能的相关性分析[J].中国眼耳鼻喉科杂志,2022,22(5):488-491,497.DOI:10.14166/j.issn. 1671-2420.2022.05.012.
[14] 张炜,贾国章,杨斌,等.突发性耳聋患者免疫及血清炎性因子变化及临床意义研究[J].临床误诊误治,2019,32(7):77-80.DOI:10.3969/j.issn.1002-3429.2019.07.019.
[15] 于阅尽,黄卫,郝亚楠,等.免疫球蛋白水平与老年突发性耳聋患者内耳微循环障碍的相关性[J].中国老年学杂志,2020,40(17):3710-3713.DOI:10.3969/j.issn.1005-9202. 2020.17.040.
[16] Maiolino L, Cocuzza S, Conti A, et al. Autoimmune ear disease: clinical and diagnostic relevance in cogan's sydrome[J]. Audiol Res, 2017,7(1):162. DOI: 10.4081/audiores.2017.162.
[17] 孙鹏,刘尧,胡劲辉,等.补体C3与C4和IL-23在系统性红斑狼疮患者感染诊断中的价值[J].中华医院感染学杂志,2019,29(4):570-573. DOI:10.11816/cn.ni.2019-180486.
[18] Xu K, Chen S, Xie L, et al. Local macrophage-related immune response is involved in cochlear epithelial damage in distinct Gjb2-related hereditary deafness models[J]. Front Cell Dev Biol, 2021,8:597769. DOI: 10.3389/fcell.2020.597769.
[19] 张梦君,戴嵩,唱得龙.补体C3、C4、抗凝蛋白及血液流变学与突发性耳聋发病及预后相关性分析[J].中华耳科学杂志,2022,20(4):554-559.DOI:10.3969/j.issn.1672-2922. 2022.04.004.
[20] 梁淑慧,李翠,刘志辉,等.系统性红斑狼疮患者血循环免疫复合物和补体水平变化及其临床意义[J].国际医药卫生导报,2010,16(1):70-73.DOI:10.3760/cma.j.issn.1007-1245.2010.01.026.
[21] Rossini BAA, Penido NO, Munhoz MSL, et al. Sudden sensorioneural hearing loss and autoimmune systemic diseases[J]. Int Arch Otorhinolaryngol, 2017,21(3):213-223. DOI: 10.1055/s-0036-1586162.
[22] Di Stadio A, Ralli M. Systemic lupus erythematosus and hearing disorders: Literature review and meta-analysis of clinical and temporal bone findings[J]. J Int Med Res, 2017,45(5):1470-1480. DOI: 10.1177/0300060516688600.
[23] Chen H, Wang F, Yang Y, et al. Characteristics of hearing loss in patients with systemic lupus erythematosus[J]. J Clin Med, 2022,11(24):7527. DOI: 10.3390/jcm11247527.
[24] Agrup C, Luxon LM. Immune-mediated inner-ear disorders in neuro-otology[J]. Curr Opin Neurol, 2006,19(1):26-32. DOI: 10.1097/01.wco.0000194143. 02171.46.
[25] Das S, Bakshi SS, Seepana R. Demystifying autoimmune inner ear disease[J]. Eur Arch Otorhinolaryngol, 2019,276(12):3267-3274. DOI: 10.1007/s00405-019-05681-5.
[26] Shi T, Lv W, Zhang L, et al. Association of HLA-DR4/HLA-DRB1*04 with Vogt-Koyanagi-Harada disease: a systematic review and meta-analysis[J]. Sci Rep, 2014,4:6887. DOI: 10.1038/srep06887.
[27] Rauch SD. Clinical management of immune-mediated inner-ear disease[J]. Ann N Y Acad Sci, 1997,830:203-210. DOI: 10.1111/j.1749-6632.1997.tb51891.x.
[28] 李熙星,陈雨濠,张光远,等.免疫介导的感音神经性听力损失患病率及治疗策略[J].临床耳鼻咽喉头颈外科杂志,2020,34(7):663-667.DOI:10.13201/j.issn.2096-7993. 2020.07.022.
[29] Missner AA, Johns JD, Gu S, et al. Repurposable drugs that interact with steroid responsive gene targets for inner ear disease[J]. Biomolecules, 2022,12(11):1641. DOI: 10.3390/biom12111641.
[30] Balouch B, Meehan R, Suresh A, et al. Use of biologics for treatment of autoimmune inner ear disease[J]. Am J Otolaryngol, 2022,43(5):103576. DOI: 10.1016/j.amjoto.2022.103576.
[31] 蔡文君,谭长强.腺病毒介导的白细胞介素-10治疗自身免疫性内耳病的实验研究[J].听力学及言语疾病杂志,2015,(6):602-606.DOI:10.3969/j.issn.1006-7299. 2015.06.009.
[32] Cai Q, Du X, Zhou B, et al. Induction of tolerance by oral administration of beta-tubulin in an animal model of autoimmune inner ear disease[J]. ORL J Otorhinolaryngol Relat Spec, 2009,71(3):135-141. DOI: 10.1159/000212116.
|